EGFR and cancer: Upon treatment with EGFR-inhibiting antibodies such as Cetuximab or Panitumumab, patients showed an overall survival benefit of 3–5 months when the cancer was wildtype for KRAS, but no benefit when the cancer was KRAS-mutated [92–94].